Busra Tan

Dr. Busra Tan

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2021 in Journal of Pharmaceutical Analysis
Verified
Journal Article
Open access
NDNilgun Duman
Nilgun Duman
ZAZahraa Alzaidi
Zahraa Alzaidi
BABüşra Aynekin
Büşra Aynekin
DTDuygu Taskin
Duygu Taskin
BTBusra Tan
Busra Tan
munis dündarmunis dündar
munis dündar
The pandemic caused by the worldwide spread of the coronavirus, which first appeared in 2019, has been named coronavirus disease 19 (COVID-19). More than 4.5 million deaths have been recorded due to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to the World Health Organization. COVID-19 Dashboard in September 2021. Apart from the wildtype, other variations have been successfully transmitted early in the outbreak although they were not discovered until March 2020. Modifications in the SARS-CoV-2 genetic material, such as mutation and recombination, have the ability to modify the viral life span, along with transitivity, cellular tropism, and symptom severity. Several processes are involved in introducing novel vaccines to the population, including vaccine manufacturing, preclinical studies, Food and Drug Administration permission or certification, processing, and marketing. COVID-19 vaccine candidates have been developed by a number of public and private groups employing a variety of strategies, such as RNA, DNA, protein, and viral vectored vaccines. This comprehensive review, which included the most subsequent evidence on unique features of SARS-CoV-2 and the associated morbidity and mortality, was carried out using a systematic search of recent online databases in order to generate useful knowledge about the COVID-19 updated versions and their consequences on the disease symptoms and vaccine development.

1 January 2024 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
ISIzem Olcay Sahin
Izem Olcay Sahin
EKEmine Karataş
Emine Karataş
MDMikail Demi̇r
Mikail Demi̇r
BTBusra Tan
Busra Tan
HPHüseyin Per
Hüseyin Per
munis dündarmunis dündar
munis dündar
Calpainopathy, also known as limb-girdle muscular dystrophy recessive type 1, is a progressive muscle disorder that impacts the muscles around the hips and shoulders. The disease is caused by defects in the CAPN3 gene and can be inherited in both recessive and dominant forms. In this retrospective study, we aimed to evaluate the clinical and molecular results of our patients with calpainopathy and to examine the CAPN3 variants in Turkish and global populations.Materials and methods: Molecular analyses were performed using the next-generation sequencing (NGS) method. CAPN3 variants were identified through the examination of various databases.Results: In this retrospective study, the cohort consisted of seven patients exhibiting the CAPN3 (NM_000070.3) mutation and a phenotype compatible with calpainopathy at a single center in Türkiye. All patients displayed high CK levels and muscle weakness. We report a novel missense c.2437G>A variant that causes the autosomal dominant form of calpainopathy. Interestingly, the muscle biopsy report for the patient with the novel mutation indicated sarcoglycan deficiency. Molecular findings for the remaining individuals in the cohort included a compound heterozygous variant (frameshift and missense), one homozygous nonsense, one homozygous intronic deletion, and three homozygous missense variants. The most common variant in the Turkish population was c.550del. In both populations, pathogenic variants were most frequently located in exon 21, according to exon length. Variants were stochastically distributed based on consequences in CAPN3 domains.Conclusion: Therefore, the NGS method proves highly effective in diagnosing rare diseases characterized by clinical heterogeneity. Assessing variants based on ethnicity holds significance in the development of precise therapies.

1 January 2024 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
ISIzem Olcay Sahin
Izem Olcay Sahin
EKEmi̇nE Karataş
Emi̇nE Karataş
MDMi̇kAi̇l Demi̇r
Mi̇kAi̇l Demi̇r
BTBusra Tan
Busra Tan
HPHüseyi̇n Per
Hüseyi̇n Per
munis dündarmunis dündar
munis dündar
This corrigendum is written to correct an error in our previous publication. The term “LGMDD4” was incorrectly spelled as “LGMDD1” throughout the article. The correct term should be “LGMDD4”. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. Link to the original article: https://journals.tubitak.gov.tr/medical/vol54/iss1/11/

Verified
Journal Article
Open access
PDF file
ŞÜŞerife Emre Ünsal
Şerife Emre Ünsal
HAHilal Akalın
Hilal Akalın
BTBusra Tan
Busra Tan
GAGülşah Akyol
Gülşah Akyol
AKAslıhan Kiraz
Aslıhan Kiraz
Background: This study investigates the relationship between clinical and hematological parameters and sub-threshold positive findings in cases with suspected hematological malignancies subjected to Janus Kinase 2 (JAK2) V617F qPCR testing. Methods: Adult patients referred to the Medical Genetics Clinic from the Erciyes University Faculty of Medicine Hematology Department between 2022 and 2024 for JAK2 V617F analysis due to suspected hematological malignancy were evaluated in this retrospective, cross-sectional study. Registered data from 2394 patients were analyzed, and 173 cases with a JAK2 V617F allele burden below 0.1% but above the negative control value were included in the study. SPSS version 25.0 software was used for statistical analysis. Results: More than half of the patients (56.6%) had no definitive hematological diagnosis at initial testing, while 28.9% developed a hematological disorder during follow-up, including overt MPN in 13.3%. Significant differences across VAF groups were observed for leukocytosis (p = 0.004), neutrophilia (p = 0.030), and monocytosis (p = 0.024), with the highest frequencies in Group 3 (0.041–0.099%). ROC analyses identified closely clustered optimal cut-offs around 0.027–0.029%, whereas no independent predictor of higher sub-threshold allele burden emerged in multivariate analysis (p > 0.05). Conclusions: Even sub-threshold levels of the JAK2 V617F mutation may exhibit specific clinical manifestations and may be associated with constitutional symptoms and leukocytosis in particular. The study findings also showed a lower awareness of the JAK2 test in clinical practice, and that it is significantly employed in off-label cases. In order to accurately interpret low-allele-burden results, molecular findings must be evaluated in conjunction with hematological parameters and appropriate clinical indications. The findings underscore the importance of applying the JAK2 V617F PCR test selectively and based on clinical suspicion.